Belgian UCB to buy commercial rights on Novartis drugs.
(ADPnews) - Aug 24, 2009 - Belgian UCB SA (EBR:UCB) said Monday it had agreed to buy the commercial rights in Germany on cardiovascular and diabetes products of Swiss pharmaceutical maker Novartis AG (VTX:NOVN).
The biopharmaceutical company will expand its pipeline with the cardiovascular drug Provas and anti-hypertension product Dafiro.
In addition, UCB will co-commercialise the two new oral anti-diabetics Jalra and Icandra.
UCB is extending its cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options, which is in line with its ambition to offer the best medicines to its patients, said Willy Cnops, vice president UCB and managing director Germany.
|Printer friendly Cite/link Email Feedback|
|Publication:||ADP News Belgium|
|Date:||Aug 24, 2009|
|Previous Article:||Belgian Sonaca to axe up to 500 jobs - report.|
|Next Article:||Belgian Leasinvest H1 2009 net current profit jumps 25% y/y.|